rs2069718

Variant summary

Our verdict is Benign.
<-10 Benign
-7
-6
-1
0
+5
+6
+9
+10
B
LB
VUS
LP
P
The variant received -12 classification points (ACMG Germline Pathogenicity v2019). BA1BP4_Strong

The NM_000619.3(IFNG):c.367-895T>C variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a cumulative frequency of 0.497 (AC=75,488) in the gnomAD database across 152,020 control chromosomes, including 19,711 homozygotes. The grpmax filtering allele frequency (95% CI) is 0.592. In-silico predictor (BayesDel (noAF)) classifies this variant as likely benign. Splicing prediction tools (SpliceAI) predict no significant impact on normal splicing. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.

Frequency

Genomes: 𝑓 0.50 ( 19711 hom., cov: 32)

Consequence

IFNG
NM_000619.3 intron

Scores

3

Clinical Significance

Not reported in ClinVar

Conservation

PhyloP100: 1.69

Publications

117 publications found
Variant links:
Genes affected
IFNG (HGNC:5438): (interferon gamma) This gene encodes a soluble cytokine that is a member of the type II interferon class. The encoded protein is secreted by cells of both the innate and adaptive immune systems. The active protein is a homodimer that binds to the interferon gamma receptor which triggers a cellular response to viral and microbial infections. Mutations in this gene are associated with an increased susceptibility to viral, bacterial and parasitic infections and to several autoimmune diseases. [provided by RefSeq, Dec 2015]
IFNG Gene-Disease associations (from GenCC):
  • immunodeficiency 69
    Inheritance: Unknown, AR Classification: MODERATE, LIMITED Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, PanelApp Australia
IFNG-AS1 (HGNC:43910): (IFNG antisense RNA 1)

Genome browser will be placed here

new If you want to explore the variant's impact on the transcript NM_000619.3, check out the Mutation Effect Viewer. This is especially useful for frameshift variants or if you want to visualize the effect of exon loss / intron retention.

Classification according to ACMG Germline Pathogenicity v2019

Classification was made for transcript

Our verdict: Benign. The variant received -12 points.

BP4
Computational evidence supports benign — no pathogenic computational or splicing signal (BP4); Splicing verdict: benign (Strong).; Germline computational verdict: benign (Strong).
BA1
GnomAD effective popmax AF >5% — BA1 stand-alone benign; GnomAD reliable popmax AF = 0.5922 — exceeds 5%% threshold (BA1 applied)

Variant Effect in Transcripts

Automated classification analysis was done for transcript: NM_000619.3. You can select a different transcript below to see updated classification assignments.

RefSeq Transcripts

Sel.
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
IFNG
NM_000619.3
MANE Select
c.367-895T>C
intron
N/ANP_000610.2P01579

Ensembl Transcripts

Sel.
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
IFNG
ENST00000229135.4
TSL:1 MANE Select
c.367-895T>C
intron
N/AENSP00000229135.3P01579
IFNG-AS1
ENST00000536914.1
TSL:5
n.337-78147A>G
intron
N/A

Frequencies

GnomAD3 genomes
AF:
0.497
AC:
75427
AN:
151902
Hom.:
19692
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.407
Gnomad AMI
AF:
0.621
Gnomad AMR
AF:
0.430
Gnomad ASJ
AF:
0.598
Gnomad EAS
AF:
0.156
Gnomad SAS
AF:
0.438
Gnomad FIN
AF:
0.437
Gnomad MID
AF:
0.627
Gnomad NFE
AF:
0.597
Gnomad OTH
AF:
0.527
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome
AF:
0.497
AC:
75488
AN:
152020
Hom.:
19711
Cov.:
32
AF XY:
0.485
AC XY:
36022
AN XY:
74284
show subpopulations
African (AFR)
AF:
0.407
AC:
16884
AN:
41456
American (AMR)
AF:
0.429
AC:
6552
AN:
15280
Ashkenazi Jewish (ASJ)
AF:
0.598
AC:
2074
AN:
3470
East Asian (EAS)
AF:
0.156
AC:
809
AN:
5170
South Asian (SAS)
AF:
0.438
AC:
2112
AN:
4818
European-Finnish (FIN)
AF:
0.437
AC:
4611
AN:
10560
Middle Eastern (MID)
AF:
0.629
AC:
185
AN:
294
European-Non Finnish (NFE)
AF:
0.597
AC:
40571
AN:
67948
Other (OTH)
AF:
0.532
AC:
1124
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
1885
3770
5655
7540
9425
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
676
1352
2028
2704
3380
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.571
Hom.:
46251
Bravo
AF:
0.491
Asia WGS
AF:
0.386
AC:
1342
AN:
3478

Local populations

ToMMo 61KJPN (+60KJPN MNV)
AF:
0.107
AC:
13108
AN:
122436
Turkish Variome
AF:
0.589
AC:
910
AN:
1546
Hom.:
272
WBBC (Westlake BioBank for Chinese) pilot
AF:
0.139
AC:
1247
AN:
8960
Hom.:
85
ABraOM SABE-WGS-1171
AF:
0.534
AC:
1251
AN:
2342
Hom.:
353

ClinVar

Not reported in ClinVar

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.81
CADD
Benign
6.9
DANN
Benign
0.68
PhyloP100
1.7
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.

Publications

Other links and lift over

For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.